Table 2.
Characteristics* of RA Patients of CORRONA doctors in CORRONA vs. not in CORRONA vs. Remainder of U.S as Identified in Medicare Administrative Data
| RA Patients of non-CORRONA doctors | SMD vs. patients of CORRONA doctors, linked to CORRONA | RA Patients of CORRONA doctors, not linked to CORRONA | SMD vs. patients of CORRONA doctors, linked to CORRONA | RA Patients of CORRONA doctors, in CORRONA | ||
|---|---|---|---|---|---|---|
| Number of RA patients, n (%) | ||||||
| 446274 | 23511 | 5532 | ||||
| Number of treating rheumatologists, n | 5,111 | 310 | 280 | |||
| Age | mean(std) | 72.62 (10.82) | 0.0219201 | 72.40 (12.27) | 0.0002204 | 72.39 (9.85) |
| Sex | Female | 332784 (74.7%) | 0.0023114 | 16763 (71.4%) | 0.0716897 | 4123 (74.6%) |
| Race | White | 378675 (85.0%) | 0.1366321 | 20226 (86.2%) | 0.1033576 | 4949 (89.5%) |
| Black | 42520 (9.5%) | 0.067486 | 2438 (10.4%) | 0.0955293 | 423 (7.7%) | |
| Hispanic | 11230 (2.5%) | 0.1695285 | 318 (1.4%) | 0.0931023 | 26 (0.5%) | |
| Native American | 2891 (0.6%) | 0.0187789 | 98 (0.4%) | 0.0131362 | 28 (0.5%) | |
| Asian Other | 4815 (1.1%) | 0.0398825 | 172 (0.7%) | 0.0032143 | 39 (0.7%) | |
| 5375 (1.2%) | 0.007899 | 220 (0.9%) | 0.0182765 | 62 (1.1%) | ||
| Region | MidWest | 102673 (24.5%) | 0.0139384 | 3249 (14.5%) | 0.2693429 | 1350 (25.1%) |
| North East | 69875 (16.7%) | 0.3212634 | 7030 (31.3%) | 0.025934 | 1619(30.1%) | |
| South | 177853 (42.4%) | 0.2147475 | 10134 (45.1%) | 0.2695225 | 1727 (32.1%) | |
| West | 68825 (16.4%) | 0.1051288 | 2055 (9.1%) | 0.1145216 | 684 (12.7%) | |
| Rural residence | 105156 (24.9%) | 0.0756817 | 5187 (23.1%) | 0.0324153 | 1169(21.7%) | |
| Comorbidities | ||||||
| COPD | 64665 (14.5%) | 0.0268574 | 3377 (14.4%) | 0.0232578 | 750 (13.6%) | |
| Diabetes | 94805 (21.2%) | 0.0825734 | 4919 (20.9%) | 0.0746882 | 994 (18.0%) | |
| Cancer | 50530 (11.3%) | 0.0122488 | 2709 (11.5%) | 0.0059731 | 648 (11.7%) | |
| MI | 6855 (1.5%) | 0.0151046 | 376 (1.6%) | 0.0201834 | 75 (1.4%) | |
| Charlson Comorbidity Index | mean(std) | 0.94 (1.75) | 0.0720511 | 0.95 (1.74) | 0.0785728 | 0.82 (1.63) |
| Health Care Utilization | ||||||
| Number of physician visits | 14.00 (10.63) | 0.0128949 | 14.52 (10.73) | 0.0627751 | 13.87 (10.12) | |
| Any hospitalization, % | 130276 (29.2%) | 0.0666433 | 7050 (30.0%) | 0.0840562 | 1450 (26.2%) | |
| Any joint surgery | 28216 (6.3%) | 0.0234481 | 1522 (6.5%) | 0.0172803 | 382 (6.9%) | |
| Patients with full-year part D, n (%) | 246133 (55%) | 12698 (54%) | 2812 (51%) | |||
| Any non-biologic DMARD**, % | 156650 (63.6%) | 0.2079756 | 8119 (63.9%) | 0.2017908 | 2060 (73.3%) | |
| Methotrexate | 114052 (46.3%) | 0.2351051 | 6083 (47.9%) | 0.2033205 | 1631 (58.0%) | |
| Sulfasalazine | 15620 (6.3%) | 0.0124709 | 643 (5.1%) | 0.0428719 | 170 (6.0%) | |
| Leflunomide | 23747 (9.6%) | 0.0631645 | 1089 (8.6%) | 0.1003173 | 326 (11.6%) | |
| Hydroxychloroquine | 52122 (21.2%) | 0.0682692 | 2233 (17.6%) | 0.0226667 | 519 (18.5%) | |
| Any Biologic**, % | 59920 (24.3%) | 0.2006718 | 3364 (26.5%) | 0.1510876 | 939 (33.4%) | |
| Abatacept | 9971 (4.1%) | 0.174194 | 746 (5.9%) | 0.0915313 | 231 (8.2%) | |
| Adalimumab | 11692 (4.8%) | 0.0483425 | 672 (5.3%) | 0.0235619 | 164 (5.8%) | |
| Certolizumab | 1416 (0.6%) | 0.0642908 | 130 (1.0%) | 0.0143671 | 33 (1.2%) | |
| Etanercept | 15071 (6.1%) | 0.0601676 | 808 (6.4%) | 0.0502699 | 215 (7.6%) | |
| Golimumab | 1080 (0.4%) | 0.0759459 | 68 (0.5%) | 0.0629324 | 31 (1.1%) | |
| Infliximab | 25151 (10.2%) | 0.2619993 | 1622 (12.8%) | 0.1824123 | 547 (19.5%) | |
| Rituximab | 5141 (2.1%) | 0.0791542 | 307 (2.4%) | 0.0572912 | 95 (3.4%) | |
| Tocilizumab | 219 (0.1%) | 0.0156767 | 33 (0.3%) | 0.0262631 | 4 (0.1%) | |
| Any DMARD or Biologic**, % | 179716 (73.0%) | 0.2893637 | 9425 (74.2%) | 0.2617548 | 2382 (84.7%) | |
| Prednisone**, % | 163678 (66.5%) | 0.0825578 | 8663 (68.2%) | 0.1193972 | 1759 (62.6%) | |
SMD = Standardized mean difference; n/a = not applicable
*
all factors described were measured during the most recent 1 year of Medicare data available.
**
assessed in Medicare part D pharmacy data in the subgroup of patients with 12 months of part D coverage